Pioneering medical database offers unprecedented insight into obesity and related conditions

A new medical database is revolutionising how healthcare professionals understand and manage obesity by automatically compiling detailed clinical data from people living with obesity and those affected by associated conditions. Spearheaded by Kobe University in Japan, the initiative is being hailed as a critical advancement for public health, research, and the development of new therapies.

“Obesity is at the root of many diseases,” says Ogawa Wataru, an endocrinologist at Kobe University.

Obesity has long been recognised as a contributing factor in a wide range of health conditions, including type 2 diabetes, hypertension, gout, coronary heart disease, and stroke. By enabling earlier intervention and more precise treatment, better data about these links has the potential to significantly improve outcomes for individuals and reduce strain on public healthcare systems.

Yet despite the widespread prevalence of obesity, obtaining reliable and comprehensive data has remained a persistent challenge. Most existing data sources are either incomplete or designed primarily for administrative purposes, such as insurance reimbursement, which limits their usefulness in clinical research or treatment planning.

Ogawa was driven to address this gap after observing the complex health challenges experienced by people living with obesity in daily clinical practice.

“Witnessing the complex health challenges faced by obese patients in daily clinical practice inspired me to seek a solution that more accurately reflects their true condition,” he explains.

To create a more accurate picture, Ogawa and his team developed a novel data collection system that links a variety of medical data points, including patient examinations, disease incidence, prescription records, and laboratory test results. The system is built on Japan’s digital medical record infrastructure and anonymises and updates patient data automatically whenever an individual visits one of the seven participating healthcare institutions.

The result is the Japan Obesity Real-world Big-data Integrated Database (J-ORBIT) — a dynamic, anonymised repository of real-world clinical information that captures the multifaceted nature of obesity and its related health conditions.

“This database system now enables the efficient collection and analysis of comprehensive clinical information related to obesity management – something that was not possible before,” notes Ogawa, who leads the project under the auspices of the Japan Society for the Study of Obesity (JASSO).

In their first published analysis, featured in the Journal of Diabetes Investigation, Ogawa and his team examined data from 1,169 individuals out of the approximately 3,000 currently enrolled in the J-ORBIT database. The findings offer valuable insights: most participants had three or more obesity-related conditions, particularly those linked to diabetes. The data also challenged some prevailing assumptions about the strength of associations between obesity and certain diseases.

Moreover, the research revealed that important treatment strategies — such as behavioural therapy — are underutilised in clinical practice. And because J-ORBIT captures a wide spectrum of clinical data, the team identified a surprisingly high prevalence of conditions not typically associated with obesity, such as menstrual irregularities and female infertility.

J-ORBIT was designed to interface with another major national database: J-DREAMS, a project run by the Japan Diabetes Society that collects data specifically from people with diabetes. Ogawa, who was also involved in managing J-DREAMS, saw an opportunity to create a sister system focused on obesity. Where both databases operate in the same institution, relevant data is extracted and automatically shared between the two.

“I was involved in the management of J-DREAMS and wanted to develop a similar database specifically for obesity management,” Ogawa explains.

This integration enables researchers working on either diabetes or obesity to access more nuanced, context-rich datasets. However, it also means that people living with both obesity and diabetes may be disproportionately represented in the J-ORBIT dataset.

One of the most impactful aspects of the new system is its ability to identify which individuals may benefit most from weight loss, and to flag appropriate treatment options tailored to their condition. This has drawn the attention of the pharmaceutical industry, particularly as new anti-obesity medications come to market.

“Several companies developing anti-obesity drugs have provided funding for the system, and some of them have already started research using the data,” says Ogawa. “So as obesity treatment undergoes a major transformation, a database like J-ORBIT will be of great importance.”

By offering a more accurate and holistic view of the lives and health of people affected by obesity, J-ORBIT represents a significant step forward. It supports not only more effective individual care but also broader public health efforts, and may well prove essential to the next generation of obesity treatment and prevention.